Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Center, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.
Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
February 2020—ArcherDX announced a nonexclusive, multiyear partnership with Illumina intended to broaden access of next-generation-sequencing–based oncology testing, including companion diagnostics for therapeutic selection, personalized monitoring, and recurrence surveillance IVD tests, upon FDA approval.
February 2020—Horizon Discovery Group went live with a new website and ecommerce system, horizondiscovery.com. Features of the website are improved navigation, including sophisticated gene-based search capabilities and advanced filtering, an intuitive, streamlined purchasing and quotation system, and comprehensive technical support and educational content.
February 2020—Vidan Diagnostics announced the availability of its β-Hydroxybutyrate 21FS prefilled reagent kits, for the quantitative in vitro determination of beta-hydroxybutyrate in serum or plasma, for use with Abbott Architect and Beckman Coulter AU systems.
February 2020—Curetis announced it has received FDA 510(k) clearance to market its Unyvero LRT Lower Respiratory Tract application cartridge for use with bronchoalveolar lavage samples to diagnose lower respiratory tract infections such as pneumonia.
February 2020—The FDA authorized marketing of the Cobas VivoDx MRSA (Roche Molecular Systems) diagnostic test based on bacterial viability and novel technology to detect methicillin-resistant Staphylococcus aureus bacterial colonization. The Cobas VivoDx MRSA test uses a new bacteriophage technology based on bioluminescence to detect MRSA from nasal swab samples in as few as five hours compared with 24 to 48 hours for conventional culture. The FDA reviewed data from performance studies in which the Cobas VivoDx MRSA test correctly identified
February 2020—Myriad Genetics announced that the FDA has approved BRACAnalysis CDx for use as a companion diagnostic to identify patients with metastatic pancreatic cancer who have a germline BRCA mutation and are candidates for treatment with PARP inhibitor olaparib (Lynparza, AstraZeneca). BRACAnalysis CDx is the first FDA-approved genetic test for this indication, the company reports. Myriad Genetics, 801-584-3600
February 2020—Verichem Laboratories announced the availability of its HDL Cholesterol Verifier kit intended for the calibration verification of HDL and LDL cholesterol assays. The kit contains high-density and low-density lipoprotein cholesterol from human serum in a ready-to-use, liquid stable format that is free of surfactants, glycols, and azide.
February 2020—Karius announced that JAMA Oncology published a clinical study showing that the Karius test detected bloodstream infections before the onset of clinical symptoms in high-risk pediatric patients with relapsed or refractory leukemia (Goggin KP, et al. Epub ahead of print Dec. 19, 2019. doi:10.1001/jamaoncol.2019.4120). The study was performed by researchers at St. Jude Children’s Research Hospital.
February 2020—Quest Diagnostics has acquired certain assets of the clinical laboratory services business of Boston Clinical Laboratories, based in Waltham, Mass.
February 2020—Foundation Medicine has received FDA approval for its FoundationOne CDx to be used as a companion diagnostic for Piqray (alpelisib) in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor–positive, human epidermal growth factor receptor 2–negative, PIK3CA-mutated advanced or metastatic breast cancer following progression on or after an endocrine-based regimen.
